Buy MDMA pills Can Tho

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buy MDMA pills Can Tho

Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. In animals, pretreatment with 5-HT 2 antagonists has been shown to attenuate neurochemical and behavioral effects of MDMA. Subjective effects were rated by psychometric rating scales. Physiological effects measured were blood pressure, heart rate, and body temperature. Adverse effects were assessed during the sessions, and after one and three days. Ketanserin attenuated MDMA-induced perceptual changes, emotional excitation, and acute adverse responses but had little effect on MDMA-induced positive mood, well-being, extroversion, and short-term sequelae. In humans, MDMA produces enhanced mood with increased well-being and extroversion, moderate derealization and slight perceptual changes Peroutka et al. The physiological response to MDMA includes elevated blood pressure and heart rate, a slight increase in psychomotor drive, and side effects such as jaw clenching, lack of appetite, and difficulty concentrating Mas et al. The roles of different neurotransmitters and receptors in mediating these effects of MDMA in humans are unclear. We have recently used the 5-HT uptake inhibitor citalopram and the dopamine D 2 antagonist haloperidol as pretreatments to MDMA in healthy subjects. Citalopram largely reduced subjective Liechti et al. These results support the hypothesis that the effects of MDMA in humans are largely dependent on 5-HT transporter-mediated enhancement of serotonergic neurotransmission. Animal studies indicate that 5-HT 2 receptors might be involved, because 5-HT 2 antagonists reduced several effects of MDMA, such as MDMA-induced serotonergic neurotoxicity, acute hyperthermia and disruption of sensorimotor gating Padich et al. Based on this evidence, we expected that also in humans some effects of MDMA would be reduced by pretreatment with a 5-HT 2 antagonist. We expected that ketanserin would attenuate some of the MDMA effects, particularly its moderate hallucinogen-like properties. All subjects were screened by a semi-structured psychiatric interview and were healthy according to history, physical examination, electrocardiogram, and blood analysis. Exclusion criteria were as follows: personal or family history of major psychiatric disorder in first-degree relatives, somatic illness and regular alcohol or substance abuse. Fourteen volunteers 13 men, 1 woman were finally included in the study. Seven had smoked cannabis a few times and four had once tried a hallucinogen. All volunteers gave their written consent after being informed by written and oral descriptions of the aim of the study, the procedures involved, and the effects and possible risks of MDMA administration. Subjects were paid for their participation. This study utilized a double-blind, placebo-controlled counterbalanced within-subjects design with four experimental conditions: placebo—placebo, ketanserin—placebo, placebo—MDMA or ketanserin—MDMA. The four sessions were separated by at least 10 days to reduce carry-over effects. Test sessions were conducted in a calm and comfortable laboratory environment. Participants were told not to eat 2 h prior to each session. At the beginning of each session volunteers took ketanserin 50 mg or placebo capsules. After 75 min MDMA 1. Psychometric ratings were performed before, shortly after drug onset and during the peak effect i. Blood pressure, heart rate and peripheral body temperature were measured 75 min before and 0, 60, 90, , and min after MDMA or placebo intake. This scale consists of 66 items yielding a global score measuring physical and general discomfort. Acute drug effects were assessed during the session, short-term sequelae the next day 24 h and again three days after the test session 72 h. In addition, sensorimotor gating of the acoustic startle reflex was measured data not shown. At the end of the study all subjects attended a debriefing interview including a retrospective comparative evaluation of their subjective experience of all four study sessions. The STAI yields a score for state and trait anxiety levels. The trait scale was administered prior to entering the study. The state scale was used during each session. Ketanserin was kindly provided by Janssen-Cilag AG Switzerland and was prepared as gelatine capsules of 50 mg. Subjects received MDMA at a single dose of 1. This dose has robust psychological and physiological effects and was carefully evaluated to minimize possible risks Vollenweider et al. Data were analyzed using Statistica 5. Tukey's post hoc tests were performed based on significant main effects or interactions. F- and p -values for significant main effects and interactions are presented in Table 1. Subjective effects of MDMA 1. MDMA produced robust effects on all measures, except for state-anxiety which was not significantly changed. MDMA significantly increased scores in all five scales. MDMA also induced a significant, although slight, increase in auditory alterations. Auditory perception was qualitatively changed e. Vigilance was reduced by MDMA and interestingly, this effect was less pronounced after ketanserin. Mean and S. Figure 2 shows peak scores of all scales of the AM mood rating. Similarly, MDMA-induced extroversion was not significantly changed. As shown in Table 1 and Figure 3 , MDMA significantly increased blood pressure, heart rate and peripheral body temperature. As seen in Figure 3 , levels of peripheral body temperature were lowered to levels of placebo when MDMA and ketanserin were given together. Ketanserin alone also lowered values compared to placebo. Acute side effects and short-term sequelae are listed in Table 2. Ketanserin significantly reduced the total of acute adverse responses to MDMA, but not short-term sequelae, as assessed after 24 and 72 h. Ketanserin alone produced very little adverse effects. A debriefing interview after completion of the study revealed that only 5 of 14 subjects could distinguish ketanserin from placebo. Nine of 14 subjects retrospectively reported that their MDMA experience was clearly less intense after ketanserin pretreatment. Five participants subjectively felt little difference between MDMA and MDMA plus ketanserin and were therefore not sure when they had received which treatment. This finding is consistent with several lines of evidence that indole hallucinogens exert their effects via agonist action at 5-HT 2A receptors Glennon ; Titeler et al. For example, it has been shown that the binding affinity for a drug for the 5-HT 2A receptor site predicts its potency for evoking hallucinations in humans Glennon et al. We have recently shown that the selective serotonin uptake inhibitor citalopram markedly reduced both psychological and physiological responses to MDMA in healthy volunteers Liechti et al. These results indicate that MDMA effects are largely dependent on transporter-mediated release of serotonin. This failure to block all effects of MDMA could be due to an insufficient dose of ketanserin. We cannot address this possibility because we used only one dose of ketanserin which, however, has proved to be effective in psilocybin subjects Vollenweider et al. The fact that ketanserin showed a relative selectivity in reducing alterations in the OAVAV scale compared to citalopram supports the involvement of 5-HT 2 receptors in mediating perceptual changes induced by released serotonin. On the other hand, only citalopram Liechti et al. Emotional excitation in the present study was reduced by ketanserin pretreatment. In contrast, pretreatment with the D 2 antagonist haloperidol failed to reduce MDMA-induced emotional excitation in an identical study design Liechti and Vollenweider b. Pretreatment with citalopram was also ineffective in this regard Liechti et al. These findings suggest that MDMA-induced emotional excitation is not primarily dependent on release of endogenous serotonin or D 2 receptor stimulation. There are several possible explanations for this unexpected result. Dopamine is generally thought to be involved in the euphoriant and arousing effects of stimulants such as d-amphetamine and cocaine Vollenweider et al. Thus, the stimulant-like properties of MDMA may be attributed partially to 5-HT 2 -mediated increase of dopamine activity. In particular, such indirect dopamine activation might have contributed to emotional excitation induced by MDMA in the present study. A role for D 1 -like receptors has also been suggested for the mediation of the acute mood altering effects of cocaine in humans Romach et al. Several subjects in the present study reported that dysphoric effects of MDMA coexisted or alternated with its pleasurable effects. Indeed, MDMA also increased scores for vigilance reduction, dazed state, inactivation, apprehension-anxiety, and produced several adverse effects. H 1 antagonists are well known for their adverse effects including sedation and dizziness. Thus, H 1 receptors are likely to be involved in the mediation of such unpleasant responses to MDMA and ketanserin. Ketanserin lowered diastolic blood pressure and body temperature when given as a pretreatment to MDMA but also when given alone compared to placebo. Although there was no statistical interaction of MDMA and ketanserin in the present study, the complete reduction of MDMA-induced increases in body temperature is consistent with animal studies demonstrating that 5-HT 2 antagonists such as MDL 11, or ketanserin block the hyperthermic effect of MDMA in rats Schmidt et al. In particular, our results indicate that the mild hallucinogen-like perceptual effects of MDMA in humans may be mediated via 5-HT 2 receptors. Eur J Pharmacol : — Drugs 40 : — Dittrich A. Pharmacopsychiat 31 : 80— Article Google Scholar. Summary of the results. Germ J Psych 9 : — Google Scholar. Geyer MA. Neuropsychopharmacology 10 : S. Glennon RA. Neuropsychopharmacology 3 : — Life Sciences 35 : — Janke W, Debus G. J Nuc Med 36 : — CAS Google Scholar. Life Sciences 28 : — Neuropsychopharmacology 21 : — Neuropsychopharmacology 22 : — J Psychopharmacol in press. European Neuropsychopharmacology 10 : — J Pharmacol Exp Ther : — Nash JF. Life Sciences 47 : — Psychopharmacology 84 : — Psychopharmacology : — Neuropsychopharmacology 1 : — Arch Gen Psychiatry 56 : — Rudnick G, Wall SC. Proc Natl Acad Sci 89 : — Am J Psychiatry : — Brain Res : 85— Eur J Pharmacol : 65— Ann NY Acad Sci : — Biochem Pharmacol 36 : — J Neurochem 62 : — Psychiatry Res 27 : — Psychopharmacology ;94 : — Nature : — Neuropsychopharmacology 19 : — NeuroReport 9 : — Psychiatry Research: Neuroimaging 83 : — Zerssen DV. Download references. The authors especially thank Mark A. Geyer, San Diego, for critical comments on the manuscript. You can also search for this author in PubMed Google Scholar. Reprints and permissions. Liechti, M. Neuropsychopharmacol 23 , — Download citation. Received : 29 November Revised : 23 February Accepted : 29 March Issue Date : 01 October Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content Thank you for visiting nature. Download PDF. Study Design This study utilized a double-blind, placebo-controlled counterbalanced within-subjects design with four experimental conditions: placebo—placebo, ketanserin—placebo, placebo—MDMA or ketanserin—MDMA. Data Analysis Data were analyzed using Statistica 5. Figure 1. Full size image. Figure 2. Figure 3. Table 2 Full size table. View author publications. Rights and permissions Reprints and permissions. About this article Cite this article Liechti, M. Copy to clipboard. Kuypers R. Ramaekers Psychopharmacology Search Search articles by subject, keyword or author. Show results from All journals This journal. Advanced search.

MDMA Is One of the Safer Illegal Drugs. But There Are Risks.

Buy MDMA pills Can Tho

This section explains how using drugs and alcohol can affect your mental health. It also explains how you can get help to stop using drugs and alcohol. This information is for people affected by mental illness in England who are 18 or over. See this 46 second video for why this is important. People use drugs and drink alcohol for lots of different reasons. Whatever your reason, using drugs or alcohol may have a long-term negative effect on you. The possible long-term effects include the following. If you use alcohol or drugs for a long time it can cause serious issues for your mental well-being. Drugs can make you more unwell and more likely to try and harm yourself or take your own life. There is also some evidence that using some drugs may cause mental illness for the first time. For example, research has shown that cannabis can increase your chances of developing psychosis or a psychotic disorder. Psychosis is a medical term. If you have psychosis you will process the world around you differently to other people. This can include how you experience, believe or view things. You might see or hear things that others do not. Or believe things other people do not. Some people describe it as a 'break from reality'. There are different terms use to describe psychosis. You can find more information about 'Psychosis' by clicking here. In this section we have listed some of the different types of substances that could have an impact on your mental health. Please be aware that this list is not a list of all substances. Taking any substances can be dangerous. They can also have bad interactions with any medications or other substances you might use. They are a specialist charity that provides information on drugs. You can find their website here: www. Cannabis is one of the most commonly used drugs in England. According to one study, 1 in 13 people aged had used it in the last year. Young people aged are more likely to use cannabis. The same study shows that just under 1 in 5 young people had used cannabis between and Some people take cannabis because it makes them feel relaxed or happy, but It can also make you feel anxious or feel paranoid. Some people may experience things that aren't real. This is a sign of drug-induced psychosis. Some studies have shown that the risk of psychosis may be higher if you:. If you have been using cannabis and you feel that it is affecting your health, make an appointment to see your GP as soon as you can. Your doctor should not judge you and should not tell other people you use drugs. Some people with a mental illness have problems using alcohol. Alcohol is legal, which means it is easier to get. It can make the feelings of some mental health issues feel worse. The long-term effects of alcohol also depend on how much you drink, and how regularly you drink it. If you drink too much on a regular basis then you could cause yourself serious physical and mental harm. Drinking can make you do something you would not normally do. This can include self-harm and suicide. Very high levels of alcohol can cause psychosis. These are drugs that contain one or more chemical substance. They produce effects that are similar to cocaine, cannabis and ecstasy. This is a common term that people use. It is used because some NPS were legal before However, the name is now wrong, because since they have been made illegal. Some new psychoactive drugs can cause confusion and a feeling of panic. You can also have hallucinations. Hallucinations can affect the way you behave. Your behaviour can become erratic and can put your own safety at serious risk. Some NPS can be very dangerous. They can kill you or hurt you very badly. There is a higher risk of this if taken with alcohol or other psychoactive drugs. In the short-term, these drugs can make you feel wide awake and alert. This can make it difficult for you to relax or get to sleep. They might cause you to have a drug-induced psychosis. In the long-term, amphetamines might make you anxious and depressed. They can also be addictive. Benzodiazepines are a type of tranquilisers. They are used to treat anxiety. They are also used as a muscle relaxant. Sometimes a doctor will tell you to take benzodiazepines to help you with anxiety. But people also buy them illegally because of their relaxing effects. They can be addictive, and so doctors only give them for a short time. In the short-term, these drugs can make you feel calmer. Depending on the type you take, they could make you feel confused or overly sleepy. Taking benzodiazepines with other drugs or alcohol can be dangerous. It can affect your breathing. It can also increase the risk of overdose and death. In the long-term, some people become addicted. This can have a big effect on their day-to-day life. In the short-term, cocaine can make you feel awake, talkative and confident. After this wears off, you can feel tired and depressed after taking it. In the long-term, cocaine use can affect how you feel. It can affect your relationships with friends and family. Cocaine is also addictive and over time you are more likely to have ongoing problems with depression, paranoia or anxiety. Cocaine can cause fits, heart attacks and strokes. If you mix it with some other drugs you are more likely to overdose or die. In the short-term, ecstasy may make you feel energetic, very happy, chatty and confident. It can also sometimes make you feel anxious, confused or trigger drug-induced psychosis. In the long-term, ecstasy use can lead to memory problems. You may also develop depression and anxiety. In the short-term, heroin can make you feel relaxed and happy. It takes away pain and can make you feel sleepy. But there is a higher risk that you could take too much or overdose with heroin than some other drugs. Heroin can be taken in lots of different ways, including by injection. However, there is a high risk of getting an infection if you inject heroin, particularly if you share needles with someone else. Heroin is very addictive. It can have serious long-term effects. You may feel that heroin becomes more important than other things in your life. This might make it harder to keep a job and affect your relationships. In the short-term, LSD may make you experience things that aren't real. Sometimes the experience will be enjoyable, and sometimes it will be frightening. This is known as a bad trip. If you have a history of mental health problems taking LSD can make it worse. If you panic during a trip on LSD it can be scary. Your local NHS trust may have a policy that says how they will help people with dual diagnosis. Check on their website to see if you can find out more about what to expect locally. If you are not already getting help with your mental health from your local mental health team, a good first step is to make an appointment to see your GP. Your GP may offer you medication and therapy to treat your mental illness. They may refer you to a drug and alcohol service to help you with your drug use. If your needs are too complicated for your GP to deal with alone, you might need more specialist support. They should offer this support and work with drug and alcohol services to give you all the help you need. The Department of Health and Social Care says that people with dual diagnosis are a key group of people who should get help from mental health services. You should not be stopped from getting help if you have drug or alcohol problems and severe mental illness. They say that people who have a severe mental illness and drug or alcohol problem should get help under the Care Programme Approach CPA. Under the CPA you will have a care co-ordinator to plan your care. They will help to write a care plan. This should account for all the different needs you might have such as:. NICE also say that you should be able to give your views on the care plan to make sure that it meets your needs. And the care plan should be shared with your carers or family if you agree. You can read the NICE guidance online here: www. There may be a team in your area which helps people with dual diagnosis. It is sometimes called the dual diagnosis team. However, not all areas of the country have them, and it may have a different name. If there isn't one in your area, you could try contacting your local community mental health team CMHT for help. As well as NHS services, you could try contacting local charities. Many charities have support services or support groups for people struggling with substance misuse. You can find some national charities listed in the Useful Contacts section below. Some people with dual diagnosis have told us that it has been difficult to get the help they need. For example, you may have been told that mental health services cannot help you because of your drink or drugs problem. But the Department of Health and Social Care is very clear that mental health services should try to help you if you have dual diagnosis. The National Institute for Health and Care Excellence NICE also say that you should not be turned away from mental health services because you have a drug or alcohol problem. You can ask for a copy of their policy for eligibility criteria. You may then be able to use this to show you are eligible for their support. If you are not happy with the services you get, talk to the person in charge of your care. This might be your GP or your 'care coordinator'. They might be able to change things for you. An 'advocate' may be able to help you to get your point of view across. You might need to make a complaint to the NHS if you do not get the help you need. Supporting someone struggling with dual diagnosis can be difficult. It might help to speak to the person you are helping, to see what support they want. For example, some people might just want someone to talk with. Other people might want more practical help, such as with booking appointments or helping them speak to professionals. We Are With You and Adfam are two charities that offer support and advice to relatives, friends and carers of those struggling with substance misuse. You can find their contact details in the Useful Contacts section below. You might also feel that you need support for yourself. You may be able to get practical support to help you with your caring responsibilities. But this can only happen if the person who you care for wants you to be involved. Speak to the mental health team if you have ideas about what services should be available or how things could work better. Drinkline This is the national alcohol helpline. They provide information and selfhelp materials for callers worried about their own drinking, and to support the family and friends of people who are drinking. They are confidential, you do not have to give your name and they can provide advice on where to get help. Telephone : Open weekdays 9am — 8pm, weekends 11am — 4pm. Webchat Drinkchat : www. Adfam This is a national charity for families and friends of drug users. It offers confidential support and information. Frank Frank provides information and advice on drugs to anyone concerned about drugs and solvent misuse, including people misusing drugs, their families, friends and carers. Open 24 hours a day, every day Text : Email : Online form here: www. Website : www. Alcohol Change UK Alcohol concern is the national organisation for alcohol misuse. It does not provide services, but they do produce information on alcohol. We Are With You This is a drug and alcohol treatment agency. Their services deal primarily with drug and alcohol problems including support for families. Al-Anon Family Groups This is a service for families and friends of alcoholics. Al-Anon family groups provide understanding, strength and hope to anyone whose life is, or has been, affected by someone else's drinking. They are recovering addicts who meet regularly to help each other stay clean. They have groups around the country. Helpline : 10am — midnight Website : www. Alcoholics Anonymous AA AA provides an opportunity for people to get together to solve their problem with alcohol and help others to recover. Cocaine Anonymous CA CA is a fellowship of men and women who use the 12 step, self-help programme to stop cocaine and all other mind-altering substances. Telephone : Open 10am — 10pm every day. DrugWise DrugWise provides information and publications on a wide range of drug related topics. PostScript A charity committed to supporting individuals to reduce the harms caused by prescribed drugs that are associated with dependence and withdrawal. They do this through a wrap-around service of one to one therapy, group therapy and a telephone support service. Release They offer advice and information on drug problems. They have expertise in legal matters surrounding drugs. Email : ask release. Turning Point This is an organisation that works with people affected by drug and alcohol misuse, mental health problems and learning disabilities. Advice and information About mental illness Learn more about conditions Drugs, alcohol and mental health. Drugs, alcohol and mental health This section explains how using drugs and alcohol can affect your mental health. Download Drugs, alcohol and mental health factsheet. Share: Contact us:. Overview There are many reasons why you might use drugs and alcohol. Some people use them to try and deal with their symptoms of their mental illness. This is called 'self-medication'. Drugs and alcohol can make the symptoms of your mental illness worse. Some drugs may make it more likely for you to get a mental illness, and they may make it harder to treat. Mental health, and drug and alcohol services should work together to give you the support you need. If you have any problems getting help, you could make a complaint. Need more advice? If you need more advice or information you can contact our Advice and Information Service. Contact us Contact us. About How can drugs and alcohol affect my mental health? Needing to take more to get the same effect. High blood pressure and strokes. Problems with your liver and pancreas. Development of certain cancers e. Difficulty obtaining or maintaining an erection. Problems with orgasms. Difficulties becoming pregnant. Feeling like you must use the drug or alcohol. This is known as being dependent. Having sudden mood changes. Having a negative outlook on life. Loss of motivation. Problems with relationships. Being secretive. Having episodes of drug-induced psychosis. What is psychosis? Drugs and effects Which substances can affect my mental health? Alcohol Also known as: bevvies, booze Some people with a mental illness have problems using alcohol. The short-term effects of an NPS depend on what you take. These drugs can also affect your judgement, which could put you at risk. When you stop taking the drug, you may feel depressed and you might find it hard to sleep. Getting help How can I get help? This should account for all the different needs you might have such as: social care, housing, and physical health. Worried about your mental health? Care Programme Approach by clicking here. Problems What can I do if I have problems trying to get help? You can find more information about: Advocacy by clicking here. Complaints by clicking here. Carer's, friends and relatives What if I am a carer, friend or relative? NICE also says that if you are caring for someone with a dual diagnosis you can: be involved in their care planning, and work with services to help those services improve. You can find more information about: Supporting someone with a mental illness by clicking here. Confidentiality — for carers, friends and relatives by clicking here. Useful contacts Drinkline This is the national alcohol helpline.

Buy MDMA pills Can Tho